Clozapine eligibility among state hospital patients

Schizophrenia Bulletin

Volumn 22, Issue 1, 1996, Pages 15-25

  Essock, Susan M ^a,b   Hargreaves, William A ^c   Dohm, Faith Anne ^d,e   Goethe, John ^e,f   Carver, Lawrence ^g   Hipshman, Lawrence ^h,i  

^a Psychological Services   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WESLEYAN UNIVERSITY   (United States)

^e CDMHAS ^*

^f INSTITUTE OF LIVING   (United States)

^g Norfolk and Norwich Hospital   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Young Adult Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ARTICLE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDICATION; DRUG SCREENING; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PUBLIC HOSPITAL; SCHIZOIDISM; SCHIZOPHRENIA;

EID: 0029925213     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/22.1.15     Document Type: Article

References (25)

1. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: The Association, 1987.
2. Chiles, J.A.; Davidson, P.; and McBride, D. Effects of clozapine on use of selection and restraint at a state hospital. Hospital and Community Psychiatry, 45:269-271, 1994.
3. Dennis, J.L.; McBride, D.; and Peterson, P.D. "Clozapine Treatment Trials at Western State Hospital: 1990-1993." Presented at the Fourth Annual National Conference on State Mental Health Agency Services Research and Program Evaluation, Annapolis, MD, October 1993.
4. Essock, S.M. Clozapine's cost effectiveness. [Letter] American Journal of Psychiatry, 152(1):152, 1995.
5. Fleiss, J.L. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons, 1981.
6. Frank, R.G. Clozapine's cost-benefits. [Letter] Hospital and Community Psychiatry, 42(1):92, 1991.
7. Goldman, H.H. Clozapine's cost-benefits. [Letter] Hospital and Community Psychiatry, 42:92-93, 1991.
8. Honigfeld, G., and Patin, J. A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry, 41:882-885, 1990.
9. Juarez-Reyes, M.G.; Shumway, M.; Battle, C.; Bacchetti, P.; Hansen, M.S.; and Hargreaves, W.A. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatric Services, 46:801-806, 1995.
10. Kane, J.M.; Honigfeld, G.; Singer, J.; Meltzer, H.Y.; and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45:789-796, 1988.
11. Lieberman, J.; Jody, D.; Geisler, S.; Alvir, J.; Loebel, A.; Szymanski, S.; Woerner, M.; and Borenstein, M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry, 50:369-376, 1993.
12. Manderscheid, R.W., and Sonnenscheim, M.A., eds. Mental Health, United States, 1992. Washington, DC: Superintendent of Documents, U.S. Government Printing Office, DHHS Publication No, (SMA) 92-1942, 1992.
13. Meltzer, H.Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin, 18(3)515-542, 1992.
14. Meltzer, H.Y.; Burnett, S.; Bastani, B.; and Ramirez, L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 141:892-897, 1990.
15. Meltzer, H.Y.; Cola, P.; Way, L.; Thompson, P.A.; Bastani, B.; Davies, M.A.; and Smitz, B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry, 150:1630-1638, 1993.
16. Reid, W.H.; Mason, M.; and Toprac, M. Savings in hospital beddays related to treatment with clozapine. Hospital and Community Psychiatry, 45:261-264, 1994.
17. Revicki, D.A.; Luce, B.R.; Weschler, J.M.; Brown, R.E.; and Adler, M.A. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry, 41:850-854, 1990.
18. Revicki, D.A.; Luce, B.R.; Weschler, J.M.; Brown, R.E.; and Adler, M.A. Clozapine's cost-benefits: In reply. [Letter] Hospital and Community Psychiatry, 42(1):93-94, 1991.
19. Rosenheck, R.; Charney, D.S.; Frisman, L.K.; and Cramer, J. Clozapine's cost effectiveness. [Letter] American Journal of Psychiatry, 152(1):153-154, 1995.
20. Sandoz Pharmaceuticals Corporation. CLOZARIL. Package insert. East Hanover, NJ: The Corporation, 1991.
21. Saveanu, T.I.; Wellage, L.; and Roth, D. "Evaluation of the Impact of Clozapine Treatment on Patients Starting Treatment in the Ohio State Hospital System." Presented at a meeting of the Ohio Department of Mental Health, Columbus, Ohio, 1994.
22. Schiller, M., and Hargreaves, W.A. Clozapine's cost effectiveness, [Letter] American Journal of Psychiatry, 152(1):151-152, 1995.
23. Terkelsen, K.G., and Grosser, R.C. Estimating clozapine's cost to the nation. Hospital and Community Psychiatry, 41:863-869, 1990.
24. Wilson, W.H. Clinical review of clozapine treatment in a state hospital. Hospital and Community Psychiatry, 43:700-703, 1992.
25. Wilson, W.H., and Claussen, A.M. "Outcome at 18 Months of Clozapine Treatment for 100 State Hospital Patients." Presented at the 34th Annual Meeting of the NIMH New Clinical Drug Evaluation Unit Program, Marco Island, FL, May 31-June 3, 1994.